Utama › Adenokarsinoma Esofagus › Texas › Houston
Kajian klinikal Adenokarsinoma Esofagus di Houston, TX
12 kajian untuk Adenokarsinoma Esofagus sedang mencari peserta di lokasi dalam dan sekitar Houston (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
Mengambil pesertaFasa 2/3
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- Ben Taub General Hospital, Houston
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Mengambil pesertaFasa 1
- University of Texas MD Anderson Cancer Center, Houston
- The University of Texas, MD Anderson Cancer Center - West Houston, Houston
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
Mengambil pesertaFasa 2/3
- University of Texas MD Anderson Cancer Center, Houston
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Mengambil pesertaFasa 1/2
- The Methodist Hospital Research Institute, Houston
- The University of Texas MD Anderson Cancer Center, Houston
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
Mengambil pesertaFasa 1
- MD Anderson, Houston
- NEXT Oncology Houston, Houston
Surveillance vs. Endoscopic Therapy for Barrett's Esophagus With Low-grade Dysplasia
Mengambil peserta
- The University of Texas MD Anderson Cancer Center, Houston
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
Mengambil pesertaFasa 3
- Research Site, Houston
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
Mengambil pesertaFasa 1
- Normunity Investigational Site, Houston
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Mengambil pesertaFasa 1
- Oncology Consultants, PA, Houston
- Oncology Consultants, PA., Houston
- The University of Texas M.D. Anderson Cancer Center, Houston
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors
Mengambil pesertaFasa 1
- MDACC, Houston
Chemotherapy With or Without Radiation or Surgery in Treating Participants With Oligometastatic Esophageal or Gastric Cancer
Mengambil pesertaFasa 2
- M D Anderson Cancer Center, Houston
A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer
Mengambil pesertaFasa 2
- Michael E. DeBakey VA Medical Center, Houston, TX, Houston
Kajian Adenokarsinoma Esofagus di bandar lain
- New York City, NY18 kajian
- Boston, MA13 kajian
- Nashville, TN11 kajian
- Arlington, VA11 kajian
- Durham, NC10 kajian
- Rochester, MN9 kajian
- Baldwin Park, CA9 kajian
- St. Louis, MO9 kajian
- Jacksonville, FL9 kajian
- Queens, NY9 kajian
- Los Angeles, CA9 kajian
- Philadelphia, PA8 kajian
Kajian lain di Houston
- Kanser Paru-paru Bukan Sel Kecil145 kajian
- Kanser Payudara126 kajian
- Kanser (semua jenis)121 kajian
- Kanser Metastatik104 kajian
- Kanser Kolorektal102 kajian
- Kanser Ovari89 kajian
- Leukemia Mieloid Akut85 kajian
- Kanser Paru-paru78 kajian
- Kanser Prostat76 kajian
- Kanser Endometrium68 kajian
- Kanser Pankreas61 kajian
- Melanoma59 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.